Abstract

Human milk oligosaccharides (HMOs) signify a unique group of oligosaccharides in breast milk, which is of major importance for infant health and development. The functional benefits of HMOs create an enormous impetus for biosynthetic production of HMOs for use as additives in infant formula and other products. HMO molecules can be synthesized chemically, via fermentation, and by enzymatic synthesis. This treatise discusses these different techniques, with particular focus on harnessing enzymes for controlled enzymatic synthesis of HMO molecules. In order to foster precise and high-yield enzymatic synthesis, several novel protein engineering approaches have been reported, mainly concerning changing glycoside hydrolases to catalyze relevant transglycosylations. The protein engineering strategies for these enzymes range from rationally modifying specific catalytic residues, over targeted subsite −1 mutations, to unique and novel transplantations of designed peptide sequences near the active site, so-called loop engineering. These strategies have proven useful to foster enhanced transglycosylation to promote different types of HMO synthesis reactions. The rationale of subsite −1 modification, acceptor binding site matching, and loop engineering, including changes that may alter the spatial arrangement of water in the enzyme active site region, may prove useful for novel enzyme-catalyzed carbohydrate design in general.

Highlights

  • Human milk oligosaccharides (HMOs) denote a group of lactose-based carbohydrate structures in human breast milk, which are considered to exert health benefits on the breast-fed baby via various mechanisms

  • The concentration and the variety of HMO-identical structures are much lower in bovine milk, which is the basis of infant formula [2,3]

  • Enzymatic transglycosylation is catalyzed by retaining glycoside hydrolases (GHs), i.e., glycosidases, which retain the configuration of the anomeric center of their products

Read more

Summary

Introduction

Human milk oligosaccharides (HMOs) denote a group of lactose-based carbohydrate structures in human breast milk, which are considered to exert health benefits on the breast-fed baby via various mechanisms. One way to accomplish production of larger and more complex HMOs is to employ transglycosylation catalyzed by glycoside hydrolases (or glycosidases, GHs), possibly in combination with use of fermentation-derived backbone structures such as LNnT or LNT as acceptor substrates for the enzymatic glycosylation. An example of current industrial use of glycosidases for transglycosylation is the production of prebiotic fructo-oligosaccharides (FOS; the basic structure is a terminal Glc unit α1,2-linked to a linear chain of two or more β2,1-linked fructose moieties) and galacto-oligosaccharides Gal units linked by β-glycosidic bonds, often with a terminal Glc moiety) [18,19,20] Today, both FOS and GOS are added to infant formula, they are not true HMOs and have been classified as unnecessary in infant formula [10]. Protein engineering to attain enhanced transglycosylation is currently manifesting itself as a valuable tool for improving enzyme performance in transglycosylation reactions and a crucial means of obtaining feasible processes

Routes to HMO Production Outside the Mammary Gland
Microbial Cell Factories
Chemical Synthesis
Enzymatic Synthesis in Vitro
Glycosidase-Catalyzed Transglycosylation
Improved Transglycosylation through Protein Engineering
Glycosynthases
Rational Design
Loop Engineering
Effect of Protein Engineering on Reaction Rates
Abundant Natural Substrates from Dairy and Agro-Industrial Side Streams
Findings
Conclusions and Perspectives
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call